Drug manufacturer Novartis has prematurely ended a study it was conducting on the drug Aliskiren. Early results of the study indicated that the drug increased the risk of serious injury for those who took the product for a year and a half or longer. The drug was found to increase incidents of kidney damage, strokes, and low blood pressure.
Aliskiren has been available since its approval by the U.S. Food and Drug Administration in 2007. The drug is manufactured and distributed in the United States under the name Tekturna.